Also categorized in Clinical Research:
A Phase I Study of Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
x hide permanently

Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis.

ncbi.nlm.nih.gov

Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis.

PLoS Med. 2018 Feb;15(2):e1002505

Authors: Waligora M, Bala MM, Koperny M, Wasylewski MT, Strzebonska K, Jaeschke RR, Wozniak A, Piasecki J, Sliwka A, Mitus JW, Polak M, Nowis D, Fergusson D, Kimmelman J